ReviewAIDS patient care and STDs2014
Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review.
Review in AIDS patient care and STDs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Factors affecting statin uptake among people living with HIV: primary care provider perspectives.BMC family practice · 2021Article
- Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection.Digestive diseases and sciences · 2020Article
- HCV infection status and care seeking among people living with HIV who use drugs in Vietnam.AIDS care · 2020Article
- Observational
- Article
- Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection.International journal of STD & AIDS · 2018Article
- Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV Observational Database.Sexual health · 2017Article
- Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.Wiener klinische Wochenschrift · 2017Article
- Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection.World journal of hepatology · 2016Article
- Hepatitis C virus: A time for decisions. Who should be treated and when?World journal of gastrointestinal pharmacology and therapeutics · 2016Review
- Treating Hepatitis C in a Ryan White-Funded HIV Clinic: Has the Treatment Uptake Improved in the Interferon-Free Directly Active Antiviral Era?AIDS patient care and STDs · 2016Article
- Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?World journal of hepatology · 2015Review
- Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.The Lancet. Infectious diseases · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This review synthesized the literature for barriers to HCV antiviral treatment in persons with HIV/HCV co-infection. Searches of PubMed, Embase, CINAHL, and Web of Science were conducted to identify relevant articles. Articles were excluded based on the following criteria: study conducted outside of the United States, not original research, pediatric study population, experimental study design, non-HIV or non-HCV study population, and article published in a language other than English. Sixteen studies met criteria and varied widely in terms of study setting and design. Hepatic decompensation was the most commonly documented absolute/nonmodifiable medical barrier. Substance use was widely reported as a relative/modifiable medical barrier. Patient-level barriers included nonadherence to medical care, refusal of therapy, and social circumstances. Provider-level barriers included provider inexperience with antiviral treatment and/or reluctance of providers to refer patients for treatment. There are many ongoing challenges that are unique to managing this patient population effectively. Documenting and evaluating these obstacles are critical steps to managing and caring for these individuals in the future. In order to improve uptake of HCV therapy in persons with HIV/HCV co-infection, it is essential that barriers, both new and ongoing, are addressed, otherwise, treatment is of little benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.